Acute Porphyria Drug Database

L01FA01 - Rituximab
Not porphyrinogenic
NP

Rationale
No CYP affinity. No conceivable effects on PXR activation. However, side effects such as nausea, anorexia and vomiting may be potentially porphyrinogenic through reduction in caloric intake.
Chemical description
Rituximab is a chimeric human-murine anti-human antigen CD20 monoclonal antibody.
Therapeutic characteristics
Rituximab is used, alone or as part of combination therapy, in the treatment of non-Hodgkins lymphomas. It is administered as an intravenous infusion. Common adverse reactions of rituximab that can be confused with an acute porphyric attack are vomiting, nausea, obstipation, abdominal pain, dorsal pain, anxiety, agitation, insomnia and tachycardia. Side effects such as nausea, anorexia and vomiting may be potentially porphyrinogenic through reduction in caloric intake.
Hepatic exposure
Metabolism and pharmacokinetics
Rituximab is metabolized as endogenous IgG. Non-CYP metabolism.
IPNet drug reports
No.

References

  1. Drug reference publications
  2. McEvoy GK, editor. Rituximab. The AHFS Drug Information 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2009. Electronic version (10.05.10). #2033
  3. Sweetman SC, editor. Martindale: The complete drug reference. Rituximab. Pharmaceutical Press 2009. #2035
  4. Summary of Product Characteristics
  5. Norwegian medicines agency. Summary of Product Characteristics (SPC). Mabthera. #2034

Similar drugs
Explore alternative drugs in similar therapeutic classes L01F / L01FA or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙